1 – 10 of 13
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
(
- Contribution to journal › Article
- 2019
-
Mark
Prediction of lymph node metastasis in breast cancer by gene expression and clinicopathological models: Development and validation within a population based cohort.
(
- Contribution to journal › Article
-
Mark
Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Abstract P4-09-03: On the development and clinical value of RNA-sequencing-based classifiers for prediction of the five conventional breast cancer biomarkers: A report from the population-based multicenter SCAN-B study
(
- Contribution to journal › Published meeting abstract
-
Mark
Stability of oestrogen and progesterone receptor antigenicity in formalin‐fixed paraffin‐embedded breast cancer tissue over time
(
- Contribution to journal › Article
-
Mark
Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative
(
- Contribution to journal › Article
- 2017
-
Mark
Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013
(
- Contribution to journal › Article
-
Mark
Quality of up to 35 years old archival breast cancer tissue in paraffinblocks for estrogen receptor evaluation
(
- Contribution to journal › Published meeting abstract
-
Mark
Quality of up to 35 years old archival breast cancer tissue in paraffin-blocks for estrogen receptor evaluation
(
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
(
- Contribution to journal › Article